Clinical trials: Cancer Colonic
Colorectal Cancer, Nausea
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients' quality of life.
- Conditions
- Colorectal Cancer, Nausea, Vomiting
- Trial name
- NCT00729677
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Beth Israel Medical Center
Colorectal Cancer, Cancer
Effectiveness and Implementation of mPATH-CRC
Study Investigators are conducting this study to learn how to best implement a new iPad program in clinical practice.
- Conditions
- Colorectal Cancer, Cancer, Rectum Cancer, Colon Cancer
- Trial name
- NCT03843957
- Testing
- mPATH-CRC, mPATH-Checkin, "high touch" Implementation strategy
- Where
- United States
- Volunteers
- 77,145 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and…
- Trial name
- NCT00419159
- Testing
- Everolimus (RAD001)
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
Use of Telehealth In-home Messaging to Improve GI (Gastrointestinal) Endoscopy Completion Rates
Low endoscopy completion rates are a major problem in the VA, causing delay or failure to receive essential care, increased clinic wait times, lost capacity, increased costs, thus limiting endoscopic screening for colorectal…
- Trial name
- GIVER (NCT00310362)
- Testing
- Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures
- Where
- United States
- Volunteers
- 3,610 people
- Sponsor
- VA Office of Research and Development
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Colorectal Cancer
Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)
PainPac is innovative in its potential to integrate with healthcare systems through electronic medical records (EMRs). PainPac leverages technology to increase patient access to interventions and uses real-time assessment to…
- Trial name
- NCT05686122
- Testing
- PainPac
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Colorectal Cancer, Liver Metastasis
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Background: Some types of inflammation may increase the risk of cancers in the intestinal track. Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and spread.
- Conditions
- Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
- Trial name
- NCT01856322
- Testing
- Sulindac, Validate assays and shipping methods
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination…
- Trial name
- NCT00778102
- Testing
- 5-FU, Irinotecan, Leucovorin
- Where
- 19 sites in Austria, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with…
- Trial name
- NCT00642603
- Testing
- capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin
- Where
- 76 sites in United States
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Sunitinib and Capecitabine for First Line Colon Cancer
This study is for patients with metastatic colorectal cancer who have not been treated with chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and Sunitinib can be used together to improve…
- Trial name
- NCT00961571
- Testing
- sunitinib and capecitabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Georgetown University
Colorectal Cancer
Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
This study uses the opinions of adults between the ages of 45 and 73 years old to develop and test an interactive nutrition module for use in an existing colorectal cancer screening intervention using virtual human technology.
- Trial name
- NCT04192071
- Testing
- virtual technology - high interactive, virtual technology - low interactive, non-colorectal cancer related module
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- University of Florida
Colorectal Cancer
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
- Trial name
- NCT00940316
- Testing
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Colorectal Neoplasms
Improving Colonoscopy Quality for Colorectal Cancer Screening in the National VA Healthcare System
High quality screening colonoscopy is critical for colorectal cancer (CRC) prevention in Veterans. There is significant variability in colonoscopy quality in VA that is directly linked to differences in CRC incidence and death.
- Trial name
- NCT04389957
- Testing
- Veterans Affairs Endoscopy Quality Improvement Program (VA-EQuIP)
- Where
- 6 sites in United States
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Colorectal Cancer
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study…
- Trial name
- Everest2 (NCT01251536)
- Testing
- Dose escalation of cetuximab, Standard first line treatment with cetuximab + Folfiri
- Where
- 30 sites in Austria, Belgium and 3 more
- Volunteers
- 108 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colonic Neoplasms
Enzastaurin for Patients With Metastatic Colorectal Cancer
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
- Trial name
- NCT00192114
- Testing
- Enzastaurin HCl
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Gynecologic Cancer, Colorectal Cancer
Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity
The purpose of this study is to incorporate feedback from cancer patients and providers to adapt, implement, and test an intervention.
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04314284
- Testing
- I Can PIC, Historical control survey, Post-intervention survey (I Can PIC participants)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Washington University School of Medicine
Colonic Neoplasms
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
The purpose of this study is to compare the concentration of four different metabolites in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different doses of Modufolin (arfolitixorin) and…
- Trial name
- NCT01681472
- Testing
- 6R-MTHF (arfolitixorin) 200 mg/m2, Levoleucovorin 200 mg/m2, 6R-MTHF (arfolitixorin) 60 mg/m2
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Isofol Medical AB
Breast Cancer, Colon Cancer
Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Primary Objective: To assess whether six-week treatment with twice daily topical Menthol application will decrease neuropathic pain as measured by the change in Brief Pain Inventory-Short Form (BPI-SF worst pain score), following…
- Conditions
- Breast Cancer, Colon Cancer, Neuropathy
- Trial name
- NCT01855607
- Testing
- topical menthol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Colorectal Adenomatous Polyps
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention
Colorectal cancer is the second leading cause of cancer-related death within the United States. Animal models and observational studies have suggested that marine-derived n-3 polyunsaturated fatty acids [PUFA] such as…
- Trial name
- NCT01661764
- Testing
- Eicosapentanoic acid and docosahexanoic acid, Oleic Acid
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Vanderbilt University
Diverticulosis, Colonic, Rectal Neoplasms
Concentration of Ertapenem in Colorectal Tissue
The purpose of this study is to determine the tissue kinetics of ertapenem in colonic tissue from three hours up to six hours (25% of dosing interval) after administration of ertapenem.
- Conditions
- Diverticulosis, Colonic, Rectal Neoplasms, Colonic Neoplasms
- Trial name
- NCT00535652
- Testing
- Ertapenem
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University of Ulm